Christine Allen (Intrepid Labs) and Andy Lewis (Quotient Sciences) discuss their strategic collaboration and the role of AI and machine learning in speeding early drug product development.
A new Contract Pharma feature discusses the strategic multi-year partnership that we share with Intrepid Labs and how we are leveraging the use of AI in formulation development, and thereby accelerating the decision-making process earlier in the pipeline.
Combining the expertise of Quotient Sciences; which offers integrated drug product development, manufacturing and clinical testing services; with the ANDROMEDA machine-learning platform from Intrepid, we aim to decrease experimental burden-halving time and the amount of API utilized in some formulation development programs by ~50%, whilst still aiming to optimize for clinical performance at the outset.
Read the full article on Contract Pharma website.